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A terbinafine impregnated subcutaneous implant was evaluated to determine if drug was released into isotonic saline over the
course of 6 months at two different temperatures, 37◦C and 4◦C. These temperatures were chosen to simulate the nonhibernating
(37◦C) and hibernating body (4◦C) temperatures of little brown bats (Myotis lucifugus). Insectivorous bats of North America,
including little brown bats, have been devastated by white nose syndrome, a fungal infection caused by Geomyces destructans. No
treatments exist for bats infected with G. destructans. Implants were placed into isotonic saline; samples were collected once per
week and analyzed with HPLC to determine terbinafine concentrations. The mean amount of terbinafine released weekly across
the 28 weeks was approximately 1.7 µg at 4◦C and 4.3 µg at 37◦C. Although significant differences in the amount released did
occur at some time points, these differences were not consistently greater or less at either of the temperatures. This study showed
that terbinafine was released from an impregnated implant over the course of 6 months at concentrations ranging from 0.02 to
0.06 µg/mL depending on temperature, which may be appropriate for little brown bats (Myotis lucifugus) infected with Geomyces
destructans, the etiologic agent of white nose syndrome.
1. Introduction
Treatment of systemic fungal infections often requires from
weeks to months of drug therapy. Consistently medicating
companion animals for this length of time can be difficult
and even more so with animals that become stressed with
handling, such as wildlife or exotic pets. Nondomesticated
animals are susceptible to stress from repeated handling and
restraint, and stress can lead to the death of hospitalized
wildlife or exotic pets [1]. Stress, including that associated
with handling in animals, has also been shown to lead to
immunosuppression and increased susceptibility to disease.
Therefore, stress associated with repeated handling for
treatment of an infection could inhibit an animal’s ability to
mount an appropriate immune response [2–4].
White nose syndrome, caused by the fungus Geomyces
destructans, is an infection that affects insectivorous bats
of North America [5–7]. Extremely high mortality rates
are associated with infection and to date, no effective
treatments have been found. If numbers of bats continue
to decline and approach extinction, members of various
affected species may need to be captured and kept in captivity
in order to preserve genetic diversity for eventual release and
repopulation. Animals may be infected with G. destructans
when captured and need antifungal treatment that is long
acting and which would require limited handling of the
animal.
Terbinafine is a fungicidal medication that inhibits the
synthesis of ergosterol which is an essential component of
fungal walls. Although no studies examining this drug in
bats have been published, studies have been performed in
other animal species [8–12]. Geomyces pannorum, a fungus
that is closely related to G. destructans, can cause infection
in humans and is susceptible to terbinafine [13, 14]; no
published reports regarding the sensitivity of G. destructans
to terbinafine are available. Terbinafine has also been useful
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Figure 1: The terbinafine impregnated implant (arrow) is shown
next to a PIT tag (microchip) and penny.
in other refractory mycotic infections in humans [15].
Geomyces destructans has been shown to be susceptible to
other antifungal agents in vitro including fluconazole, but
terbinafine has a better safety profile than many other
commonly used antifungal medications [16–18].
The goal of this study was to investigate a terbinafine
impregnated implant designed for subcutaneous placement
over the dorsum of bats infected with G. destructans; the in
vitro release of terbinafine from the implant was evaluated at
two different temperatures, 4◦C and 37◦C, over the course
of approximately 6 months. The two temperatures were
chosen because they are similar to the body temperatures
of hibernating (4◦C) and nonhibernating (37◦C) bats. This
initial trial was designed to determine if terbinafine would
release from the implant over the course of many months
without degradation of the implant in an in vitro setting.
2. Materials and Methods
Implants were constructed by Melatek, LLC (Madison, WI,
USA) based on protocols used to make Ferretonin implants.
These implants are stable for approximately 5 years if kept
at 4◦C (T. Cairns, pers. comm.). Briefly, terbinafine HCl
(Sigma-Aldrich, Co., St. Louis, MO, USA) was mixed with
medical grade elastomer to a calculated concentration so
that each implant would contain 0.5mg of terbinafine.
The mixture was placed into a mold where it cured and
was then cut into individual implants. Each implant was
approximately the size of a passive integrated transponder
(PIT) tag (microchip) as shown in Figure 1. Cured medical
grade elastomer is dimensionally and thermally stable,
resistant to oxidation and sunlight, and does not become
hard with age (T. Cairns, pers. comm.). Implants were kept at
4◦C for approximately onemonth according tomanufacturer
instructions prior to placement into saline.
For in vitro analysis, implants were individually placed
into 25mL of isotonic saline in glass containers. Five
implants were kept at 4◦C and five were kept at 37◦C. Every
7 days, the solution in each container was mixed to ensure
homogeneity and 350 µL was then removed and placed into
a cryo-tube for analysis. Following sample removal, isotonic
Table 1: Mean (SD) amount of terbinafine (µg) released from
0.5mg implants in isotonic saline at two different temperatures,
4◦C and 37◦C. A t-test or Mann-Whitney/Wilcoxon 2-sample test
was performed to determine if means differed between the two
temperatures at the different time points. A P of <0.05 (∗) denotes
a significant difference.
Weeks after initial
placement into saline
4◦C 37◦C
P value
Mean SD Mean SD
1 3.4 0.6 4.8 0.2 <0.01∗
2 20.3 12.7 5.2 4.6 0.04∗
3 19.9 21.2 −8.0 6.1 0.02∗
4 3.7 15.1 20.3 21.3 0.19
5 5.7 1.9 −3.2 23.0 0.75
6 −2.3 10.6 12.6 10.8 0.06
7 −20.2 55.6 −1.6 21.0 0.70
8 6.0 54.3 14.2 7.5 0.17
9 10.9 14.7 14.4 12.4 0.70
10 −0.4 8.9 4.2 33.2 0.60
11 −2.1 6.0 5.5 6.3 0.09
12 −1.4 8.6 1.0 4.8 0.60
13 5.7 6.4 6.3 4.7 0.88
14 3.6 5.5 −4.7 9.3 0.12
15 −4.5 4.9 −3.7 8.5 0.86
16 4.7 8.4 −0.4 11.2 0.44
17 −3.2 3.7 11.0 5.5 <0.01∗
18 −0.8 1.8 2.9 5.6 0.19
19 12.4 3.3 13.4 6.9 0.78
20 −0.2 11.6 0.4 2.3 0.91
21 −0.1 8.8 8.8 6.5 0.10
22 1.5 6.6 15.0 27.7 0.32
24 3.6 4.2 −6.0 21.4 0.35
25 −12.7 7.5 −9.5 5.0 0.45
26 0.6 7.1 10.2 4.1 0.03∗
27 −6.3 2.5 −2.6 3.3 0.08
28 −1.9 4.9 6.7 6.4 0.04∗
saline (350 µL) was added to the container so the volume was
kept consistent. Samples were collected for a total of 28 weeks
and were kept in a −80◦C freezer until analysis.
Saline samples were analyzed using HPLC with ultravi-
olet absorption. The system consisted of a 2695 separations
module, a 2487 absorbance detector (Waters, Milford, MA,
USA). Terbinafine was extracted from saline samples using a
hexane extraction and was separated on a Symmetry Shield
C18 (4.6 × 100mm, 5 µm) column with a guard column.
The mobile phase was a mixture of (A) 20mM phosphoric
acid with 0.1% triethylamine adjusted to pH 3.0 and (B)
acetonitrile (65 : 35). The flow rate was 1.1mL/min and the
column temperature ambient. Absorbance was measured at
224 nm.
Standard curves for analysis were prepared by fortifying
saline with terbinafine to produce a linear concentration
range of 5–1500 ng/mL. Average recovery for terbinafine was
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5
15
25
35
45
55
65
1 3 5 7 9 11 13 15 17 19 21 24 26 28
M
ea
n
 µ
g 
of
 te
rb
in
afi
n
e 
re
le
as
ed
Weeks since initial placement of implant into isotonic saline 
−5
−15
−25
2 4 6 8 10 12 14 16 18 20 22 25 27
4◦C
37◦C
Figure 2: Terbinafine impregnated implants were placed into isotonic saline at 4◦C (n = 5) and 37◦C (n = 5). Samples were collected every
7 days and terbinafine concentrations were determined with HPLC. A sample was not collected during week 23. The mean amount (µg) of
terbinafine released (±SD) at the different temperatures is shown over the course of 6 months.
95% while intra- and interassay variability were less than
10%. The lower limit of quantification was 5 ng/mL.
Following HPLC analysis, the amount of terbinafine
released by each implant during each interval was calculated.
The mean release of terbinafine with standard deviations
was calculated for the different temperatures at each time
point. Data was tested for normalcy with a Bartlett’s test
for inequality of variances. If the values were normally
distributed, a t-test was performed to determine if a
significant difference in amount of terbinafine released was
present at the two temperatures. If the data was not normally
distributed, a Mann-Whitney/Wilcoxon two-sample test was
used to determine if differences existed. Significance was set
at P < 0.05 and analysis was performed with EpiInfo (CDC,
Atlanta, GA, USA).
3. Results
Samples were collected and analyzed with HPLC for a total of
28 weeks after initial placement into isotonic saline. A sample
was not collected during week 23. Themean amount released
from the implants at the two different temperatures during
the 28 weeks is shown in Table 1/Figure 2. The amount
released from the implants at 37◦C was significantly greater
than 4◦C at the 1 (P < 0.01), 17 (P < 0.01), 26 (P =
0.03), and 28 (P = 0.04) week time points; the amount
released from implants at 4◦C was greater than 37◦C at the
2 (P = 0.04) and 3 (P = 0.02) week time points. The mean
amount of terbinafine released weekly across the 28 weeks
was approximately 1.7 µg at 4◦C and 4.3 µg at 37◦C.
4. Discussion
The implant was evaluated at two different temperatures
because of the differing rates of metabolism between hiber-
nating and nonhibernating bats [19]. It was hypothesized
that more terbinafine would be released at 37◦C than at 4◦C.
If terbinafine was released from implants at different rates
at the different temperatures, excessively high concentrations
may be reached in nonhibernating bats or suboptimal con-
centrations may be reached in hibernating bats. In this study,
there were significant differences between the release rates
at 6 of the time points, but the levels were not consistently
higher at one temperature compared to the other. Variations
in the amount of drug released from the implants occurred
at both temperatures and led to large standard deviations
at some time points. This variation in drug release may
have been due to slight differences in the temperature within
the incubator/refrigerator or from incomplete mixing of
the solution prior to sampling. Additionally, the measured
concentrations at some time points indicated that the release
was negative. These values may have been due to little if
any release following the previous sample collection and
replacement with saline which led to an overall lower
concentration in the container.
Terbinafine has been used in refractory fungal infections
with success [15] and typically has fewer adverse effects than
other antifungal medications [17]. Unpublished research
has shown that G. destructans is susceptible to terbinafine,
but minimum inhibitory concentrations (MIC) are not
available. In vitro susceptibility of other fungi and yeasts
ranges from 0.001 to 128.0 µg/mL [17]. The mean amount
of terbinafine released weekly during the 28 weeks was 1.7 µg
at 4◦C and 4.3 µg at 37◦C. Assuming the typical little brown
bat (Myotis lucifugus) weighs approximately 10 grams and
this in vitro test is an appropriate approximation of the
amount of terbinafine that would be released in vivo, bats
would have a circulating concentration ranging from 0.02
to 0.06 µg/mL for approximately 6 months depending on
body temperature. These circulating concentrations would
fall within the MIC for many pathogenic fungi and yeast,
however, further studies are needed to determine the MIC
of G. destructans. Additionally, initial clinical trials in little
brown bats are currently being performed (M. Souza,
pers. comm.). Implants were placed subcutaneously over
4 Journal of Drug Delivery
the dorsum of bats infected with G. destructans and safety
and efficacy of the implants will be determined. Results are
not yet available, but skin samples will be evaluated with
HPLC to determine terbinafine concentrations.
5. Conclusions
In conclusion, terbinafine was released from the implant
over the course of 6 months with no consistent significant
differences at two different temperatures, 37◦C and 4◦C.
However, without in vivo absorption, metabolism and
clearance, it is difficult to know whether this implant will
release therapeutic amounts of terbinafine in G. destructans
infected bats. This research was the first step to determine if
terbinafine would release from the implant over an extended
period of time and what amounts might be released. Future
research will need to examine the implants in animals to
determine the concentration of systemic terbinafine over
time. Following further investigation, this implant may
provide a long term treatment for G. destructans infected
bats that requires handling only once at the beginning of
treatment.
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